Gallic Acid Enhances the Anti-Cancer Effect of Temozolomide in Human Glioma Cell Line via Inhibition of Akt and p38-MAPK Pathway

(1) Background: Temozolomide (TMZ), an oral alkylating agent, is used to treat malignant gliomas and other difficult-to-treat tumors. TMZ can enter the cerebrospinal fluid p.o. (per os) does not need hepatic metabolism for activation of its use as a standard chemotherapeutic regimen after surgical resection glioma brain. However, prognosis remains poor most patients, survival rate still unsatisfactory. Gallic acid (Ga) secondary metabolite existent in numerous plants. Ga shows various bioactivities, including antioxidant, anti-inflammatory, anticancer antimicrobial effects. In this study, latent enhanced anti-cancer efficacy TMZ-treated U87MG cells (a human line) was evaluated. (2) Methods: The cell line cultured 24 h. were incubated with alone, or their combination time points. Cell viability drug index evaluated by XTT-based analysis isobologram analysis, respectively. DNA destruction intracellular reactive oxygen species (ROS) generation analyzed flow cytometer. expression proteins assessed via Western blotting. (3) Results: Compared action alone TMZ/Ga augmented inhibition cellular apoptotic level line. This effect correlated decreased Bcl-2 p-Akt, corresponded p38 mitogen-activated protein kinase (MAPK) pathway. addition, suppressed TMZ-promoted ROS generation. (4) Conclusions: augment repression Akt enhancement MAPK Our results offer novel probable approach medical treatment glioma.